Browse Venture capital companies topic

Product development subtopic

Articles 1-24 out of 24 article(s) Title Author Type Date Words Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID[R], Presented at ASCO Plenary Session. Clinical report May 31, 2009 1721 Personalized Anti-Cancer Vaccine Pivotal Phase III Results to be Presented at ASCO Plenary Session. May 20, 2009 1011 T2 Biosystems Announces Strategic Investment and Technology Development Agreement with In-Q-Tel. Oct 17, 2008 585 Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%. Oct 7, 2008 2298 Israel: Percello raises $12 million to fund accelerated growth. Sep 11, 2008 600 India: Percello Raises $12 Million to Fund Accelerated Growth. Sep 10, 2008 381 Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial. Financial report Jul 17, 2008 1194 Biovest International Reaffirms Its Confidence in the Ongoing Unblinding of the BiovaxID(TM) Phase 3 Data Based on a Track Record of Eliciting an Immune Response in 80% of Patients. Clinical report Dec 21, 2007 719 Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma. Oct 16, 2007 1212 Accentia Biopharmaceuticals Announces Unblinding and Analysis of Fast Tracked Phase 3 Trial for BiovaxID. Oct 16, 2007 1184 Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma. Jun 28, 2007 1111 Interim Analysis of Anti-Cancer Vaccine, BiovaxID, to be Conducted. Jun 13, 2007 1366 Accentia Biopharmaceuticals' Majority-Owned Subsidiary, Biovest, Receives Request From the Independent Data Monitoring Committee to Conduct Interim Analysis of Anti-Cancer Vaccine, BiovaxID. Jun 13, 2007 1366 FastSoft Receives $4 Million Series A Funding Led by Miramar. Jun 11, 2007 433 Adnexus Therapeutics Announces Presentation of Interim Phase I Results for CT-322, First Adnectin Therapeutic in Humans. Feb 2, 2007 825 Biovest International's Phase 3 Therapy for Follicular Lymphoma Receives Independent Support From Newly Published Phase 2 Trial Data. Oct 19, 2006 807 Biovest International Gains Key Regulatory Approval for Clinical Trial Sites in Russia; Biovest to open 14 new clinical sites, accelerating patient recruitment. Jul 18, 2006 865 FDA Gives Permission to Use Very Sensitive Molecular Evidence of Cancer in BiovaxID Pivotal Phase 3 Clinical Trial: Company Intends to Use Blood Test to File Application for Accelerated Approval. May 16, 2006 1105 FDA Gives Permission to Use Very Sensitive Molecular Evidence of Cancer in BiovaxID Pivotal Phase 3 Clinical Trial:; Biovest Intends to Use Blood Test to File Application for Accelerated Approval. May 16, 2006 1074 FDA Grants Biovest International Fast Track Status for BiovaxID(TM); Personalized Vaccine for Follicular Non-Hodgkin's Lymphoma Receives Fast Track Status from FDA. May 11, 2006 906 FDA Grants Accentia Biopharmaceuticals, Inc.'s Majority-Owned Subsidiary Fast Track Status for BiovaxID(TM); Personalized Vaccine for Follicular Non-Hodgkin's Lymphoma Receives Fast Track Status from FDA. May 11, 2006 916 Accentia Biopharmaceuticals Announces Financial Results For Fiscal Year 2005. Jan 5, 2006 1348 Accentia Biopharmaceuticals Announces That Follow-up Data from the Phase II Clinical Trial of BiovaxID(TM) Will Be Presented at the Annual Meeting of the American Society for Hematology. Dec 1, 2005 826 Biovest International Announces that It Will Report New Follow-up Data from Its Phase 2 Clinical Trial of BiovaxID(TM) at the Annual Meeting of the American Society for Hematology. Dec 1, 2005 694